Zefamenib clinical trials
Its developmentBy Institut de Recherches Internationales Servier (I.R.I.S.) and BioNova Pharmaceuticals (Shanghai), step by step2 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses zefamenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zefamenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 2 |
Who runs them
Industry 2 · Other 1
Institut de Recherches Internationales Servier (I.R.I.S.) (1) · BioNova Pharmaceuticals (Shanghai) LTD. (1) · The First Affiliated Hospital of Soochow University (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test zefamenib.
- Dec 2026A Study of BN104 in the Treatment of Acute LeukemiaPhase 1/2 · Institut de Recherches Internationales Servier (I.R.I.S.)
Studies
Open first, then newest update. How each study uses zefamenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute LeukemiaRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07101497Written as BN104 monotherapyHow we know
- A Study of BN104 in the Treatment of Acute LeukemiaActive, not recruitingPhase 1/2Institut de Recherches Internationales Servier (I.R.I.S.)NCT06052813Written as BN104 monotherapyHow we know
- The Effect of Food on the Pharmacokinetics of BN104 TabletsCompletedPhase 1BioNova Pharmaceuticals (Shanghai) LTD.NCT06724549Written as BN104How we know
Codes
What other systems call zefamenib · ClinicalTrials.gg INT017127
- UNII (FDA) L25B98F8W3ZEFAMENIBOne source FDA
- NCI Thesaurus C223320ZefamenibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | L25B98F8W3 | ZEFAMENIB | One source FDA |
| NCI Thesaurus | C223320 | Zefamenib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.